Division of Intrexon Corp.
Latest From Theragen Inc.
Gene Therapy; Cardiovascular; Restenosis. CardioGene has a patented method of promoting gene expression in vascular smooth muscle cells and endothelial cells. The technology also incorporates a double balloon catheter for delivery of the product to theinner wall of the blood vessel. CardioGene also has nine patent applications that include the use of adenovirus vectors to carry genes to vascular smooth muscle cells and means of coating stents with recombinant DNA.
This articles reviews 1994's intense merger activity. The big hospital and home infusion mergers have created enormous national organizations, but the rise of locally powerful integrated systems undercuts their clout. Consolidation in the device industry reflects the devaluation of incremental technological improvements and providers' needs to cut their list of separate suppliers. Diagnostics gained new players as biotechs, which believe they can successfully mix diagnostic and therapeutic product marketing efforts, bought into the business. Drug firms were energetic acquirors, but few of their deals were copycat transactions. Most were driven by very different motivations, including the idea of acquiring the capability to cover an entire episode of care, not merely the drug used.